Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. by McMurray, J, Gerstein, H, Holman, R, Pfeffer, M

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC by De Battista D, Zamboni F, Gerstein H, Sato S, Markowitz TE, Lack J, Engle RE, Farci P

Get full text

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE) by Mc Morrow, L, Becker, F, Leal, J, Gray, A, Coleman, R, Gerstein, H, Ryden, L, Holman, R

The effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trial... by Zoungas, S, Arima, H, Gerstein, H, Holman, R, Woodward, M, Reaven, P, Hayward, R, Craven, T, Coleman, R, Chalmers, J

Microvascular outcomes in type 2 diabetes - Authors' reply by Zoungas, S, Gerstein, H, Holman, R, Reaven, P, Woodward, M, Arima, H, Coleman, R, Chalmers, J, Collaborators on Trials of Lowering Glucose (CONTROL) writing group

Effect of ramipril on the incidence of diabetes. by Bosch, J, Yusuf, S, Gerstein, H, Pogue, J, Sheridan, P, Dagenais, G, Diaz, R, Avezum, A, Lanas, F, Probstfield, J, Fodor, G, Holman, R

Incidence of diabetes following ramipril or rosiglitazone withdrawal by Holman, R, Zinman, B, Yusuf, S, Sheridan, P, Anand, S, Bosch, J, Conget, I, Davies, M, Pirags, V, Dagenais, G, Pogue, J, Zimmet, P, Gerstein, H

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. by Punthakee, Z, Bosch, J, Dagenais, G, Diaz, R, Holman, R, Probstfield, J, Ramachandran, A, Riddle, M, Rydén, L, Zinman, B, Afzal, R, Yusuf, S, Gerstein, H

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. by Gerstein, H, Yusuf, S, Bosch, J, Pogue, J, Sheridan, P, Dinccag, N, Hanefeld, M, Hoogwerf, B, Laakso, M, Mohan, V, Shaw, J, Zinman, B, Holman, R

Intensive glucose control and macrovascular outcomes in type 2 diabetes. by Turnbull, F, Abraira, C, Anderson, R, Byington, R, Chalmers, J, Duckworth, W, Evans, G, Gerstein, H, Holman, R, Moritz, T, Neal, B, Ninomiya, T, Patel, A, Paul, S, Travert, F, Woodward, M

Associations of omega-3 fatty acid supplement use with cardiovascular disease risks meta-analysis of 10 trials involving 77 917 individuals by Aung, T, Halsey, J, Kromhout, D, Gerstein, H, Marchioli, R, Tavazzi, L, Geleijnse, M, Rauch, B, Ness, A, Galan, P, Chew, E, Bosch, J, Collins, R, Lewington, S, Armitage, J, Clarke, R

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. by Holman, R, Bethel, M, Chan, J, Chiasson, J, Doran, Z, Ge, J, Gerstein, H, Huo, Y, McMurray, J, Ryden, L, Liyanage, W, Schröder, S, Tendera, M, Theodorakis, M, Tuomilehto, J, Yang, W, Hu, D, Pan, C

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial by Holman, R, Bethel, M, Chan, J, Chiasson, J, Doran, Z, Ge, J, Gerstein, H, Huo, Y, McMurray, J, Ryden, L, Liyanage, W, Schroder, S, Tendera, M, Theodorakis, M, Tuomilehto, J, Yang, W, Hu, D, Pan, C

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-contro... by Holman, R, Coleman, R, Chan, J, Chiasson, J, Feng, H, Ge, J, Gerstein, H, Gray, R, Huo, Y, Lang, Z, McMurray, J, Rydén, L, Schröder, S, Sun, Y, Theodorakis, M, Tendera, M, Tucker, L, Tuomilehto, J, Wei, Y, Yang, W, Wang, D, Hu, D, Pan, C, Ace Study Group